Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.

Ann Rheum Dis · 2017 · PMC5264306 · PMID 27474763

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

4 In the pathways examined, there was a notable trend for upregulation of genes at baseline that are relevant to disease pathogenesis and a subsequent downregulation upon canakinumab treatment.

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.